Current management of gastric cancer

Gastric cancer is a disease with high incidence and mortality in our population. The prognosis of patients with this disease is closely related to the neoplasm stage at diagnosis, including the following characteristics of the tumor: extension into the gastric wall thickness, spread to locoregional lymph nodes and the ability to generate distant metastases, as described by the TNM classification. For localized tumors characterized only by invasion of mucosa or submucosa at diagnosis, survival at 5 years is between 70 and 95% with exclusive surgical management; however, when extension into the gastric wall is higher and/or there is locoregional nodal involvement, survival decreases to 20-30% at 5 years. Currently, at high-volume centers, the extent of gastrectomy is individualized based on several parameters, which in an increasing number of cases allows a total gastrectomy with D2 lymphadenectomy and preservation of the spleen and pancreas. This improved procedure increases the chance of R0 surgery and improves the relationship between resected and affected lymph nodes, resulting in a decreased risk of the long-term locoregional recurrence. To improve these results, different therapeutic strategies combining chemotherapy or chemoradiotherapy with surgery have been tested. Previously, the Intergroup 0116 clinical trial, published in 2001, which changed clinical practice in the United States, showed that adjuvant chemoradiotherapy improved survival (from 26 to 37 months overall survival) of these patients. In Europe, perioperative chemotherapy has been considered the standard treatment, since the publication of two randomized phase III trials showed an increase at 5 years survival in the group treated with chemotherapy.

Saved in:
Bibliographic Details
Main Authors: Viúdez-Berral,Antonio, Miranda-Murua,Coro, Arias-de-la-Vega,Fernando, Hernández-García,Irene, Artajona-Rosino,Alicia, Díaz-de-Liaño,Álvaro, Vera-García,Ruth
Format: Digital revista
Language:English
Published: Sociedad Española de Patología Digestiva 2012
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082012000300006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-01082012000300006
record_format ojs
spelling oai:scielo:S1130-010820120003000062012-05-22Current management of gastric cancerViúdez-Berral,AntonioMiranda-Murua,CoroArias-de-la-Vega,FernandoHernández-García,IreneArtajona-Rosino,AliciaDíaz-de-Liaño,ÁlvaroVera-García,Ruth Gastric cancer Gastric cancer surgery Perioperative chemotherapy Adjuvant chemotherapy Adjuvant chemoradiotherapy Gastric cancer is a disease with high incidence and mortality in our population. The prognosis of patients with this disease is closely related to the neoplasm stage at diagnosis, including the following characteristics of the tumor: extension into the gastric wall thickness, spread to locoregional lymph nodes and the ability to generate distant metastases, as described by the TNM classification. For localized tumors characterized only by invasion of mucosa or submucosa at diagnosis, survival at 5 years is between 70 and 95% with exclusive surgical management; however, when extension into the gastric wall is higher and/or there is locoregional nodal involvement, survival decreases to 20-30% at 5 years. Currently, at high-volume centers, the extent of gastrectomy is individualized based on several parameters, which in an increasing number of cases allows a total gastrectomy with D2 lymphadenectomy and preservation of the spleen and pancreas. This improved procedure increases the chance of R0 surgery and improves the relationship between resected and affected lymph nodes, resulting in a decreased risk of the long-term locoregional recurrence. To improve these results, different therapeutic strategies combining chemotherapy or chemoradiotherapy with surgery have been tested. Previously, the Intergroup 0116 clinical trial, published in 2001, which changed clinical practice in the United States, showed that adjuvant chemoradiotherapy improved survival (from 26 to 37 months overall survival) of these patients. In Europe, perioperative chemotherapy has been considered the standard treatment, since the publication of two randomized phase III trials showed an increase at 5 years survival in the group treated with chemotherapy.Sociedad Española de Patología DigestivaRevista Española de Enfermedades Digestivas v.104 n.3 20122012-03-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082012000300006en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Viúdez-Berral,Antonio
Miranda-Murua,Coro
Arias-de-la-Vega,Fernando
Hernández-García,Irene
Artajona-Rosino,Alicia
Díaz-de-Liaño,Álvaro
Vera-García,Ruth
spellingShingle Viúdez-Berral,Antonio
Miranda-Murua,Coro
Arias-de-la-Vega,Fernando
Hernández-García,Irene
Artajona-Rosino,Alicia
Díaz-de-Liaño,Álvaro
Vera-García,Ruth
Current management of gastric cancer
author_facet Viúdez-Berral,Antonio
Miranda-Murua,Coro
Arias-de-la-Vega,Fernando
Hernández-García,Irene
Artajona-Rosino,Alicia
Díaz-de-Liaño,Álvaro
Vera-García,Ruth
author_sort Viúdez-Berral,Antonio
title Current management of gastric cancer
title_short Current management of gastric cancer
title_full Current management of gastric cancer
title_fullStr Current management of gastric cancer
title_full_unstemmed Current management of gastric cancer
title_sort current management of gastric cancer
description Gastric cancer is a disease with high incidence and mortality in our population. The prognosis of patients with this disease is closely related to the neoplasm stage at diagnosis, including the following characteristics of the tumor: extension into the gastric wall thickness, spread to locoregional lymph nodes and the ability to generate distant metastases, as described by the TNM classification. For localized tumors characterized only by invasion of mucosa or submucosa at diagnosis, survival at 5 years is between 70 and 95% with exclusive surgical management; however, when extension into the gastric wall is higher and/or there is locoregional nodal involvement, survival decreases to 20-30% at 5 years. Currently, at high-volume centers, the extent of gastrectomy is individualized based on several parameters, which in an increasing number of cases allows a total gastrectomy with D2 lymphadenectomy and preservation of the spleen and pancreas. This improved procedure increases the chance of R0 surgery and improves the relationship between resected and affected lymph nodes, resulting in a decreased risk of the long-term locoregional recurrence. To improve these results, different therapeutic strategies combining chemotherapy or chemoradiotherapy with surgery have been tested. Previously, the Intergroup 0116 clinical trial, published in 2001, which changed clinical practice in the United States, showed that adjuvant chemoradiotherapy improved survival (from 26 to 37 months overall survival) of these patients. In Europe, perioperative chemotherapy has been considered the standard treatment, since the publication of two randomized phase III trials showed an increase at 5 years survival in the group treated with chemotherapy.
publisher Sociedad Española de Patología Digestiva
publishDate 2012
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082012000300006
work_keys_str_mv AT viudezberralantonio currentmanagementofgastriccancer
AT mirandamuruacoro currentmanagementofgastriccancer
AT ariasdelavegafernando currentmanagementofgastriccancer
AT hernandezgarciairene currentmanagementofgastriccancer
AT artajonarosinoalicia currentmanagementofgastriccancer
AT diazdelianoalvaro currentmanagementofgastriccancer
AT veragarciaruth currentmanagementofgastriccancer
_version_ 1755938614489907200